Circulating adiponectin and breast cancer risk: A systematic review and meta-analysis

International Journal of Epidemiology

Volumn 43, Issue 4, 2014, Pages 1226-1236

  Macis, Debora ^a   Guerrieri Gonzaga, Aliana ^a   Gandini, Sara ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Biomarker; Breast cancer risk; Circulating adiponectin

Indexed keywords

ADIPONECTIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RISK; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BLOOD; BREAST NEOPLASMS; FEMALE; RISK;

ADIPONECTIN; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; RISK;

EID: 84905658521     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyu088     Document Type: Article

References (55)

1. Van Den Brandt PA, Spiegelman D, Yaun SS et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
2. Morimoto LM,White E, Chen Z et al.Obesity, body size, and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
3. Lahmann PH, Hoffmann K, Allen N et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and nutrition (EPIC). Int J Cancer 2004;111:762-71.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
5. Cecchini RS, Costantino JP, Cauley JA et al. Body mass index and the risk for developing invasive breast cancer among highrisk women in Nsabp P-1 and Star Breast Cancer Prevention Trials. Cancer Prev Res (Phila) 2012;5:583-92.
6. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-50.
7. Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: A link between obesity and cancer. Expert Opin Investig Drugs 2006;15:917-31.
8. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose- specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
9. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010;95:911-19.
10. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-35.
11. Gunter MJ, Hoover DR, Yu H et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60.
12. Kabat GC, Kim M, Caan BJ et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009;125:2704-10.
13. Goodwin PJ, Ennis M, Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
14. Macis D, Gandini S, Guerrieri-Gonzaga A et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 2012;30:151-57.
15. Miyoshi Y, Funahashi T, Kihara S et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9:5699-704.
16. Mantzoros C, Petridou E, Dessypris N et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-07.
17. Chen DC, Chung YF, Yeh YTet al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109-14.
18. Tworoger SS, Eliassen AH, Kelesidis T et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007;92:1510-16.
19. Korner A, Pazaitou-Panayiotou K, Kelesidis T et al.: Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041-48.
20. Tian YF, Chu CH, Wu MH et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 2007;14:669-77.
21. Hou WK, Xu YX, Yu T et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007;120:1592-96.
22. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007;22:117-21.
23. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010;119:367.
24. Gaudet MM, Falk RT, Gierach GL et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol 2010;34:580-86.
25. Shahar S, Salleh RM, Ghazali AR, Koon PB, Mohamud WN. Roles of adiposity, lifetime physical activity and serum adiponectin in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev 2010;11:61-66.
26. Al-Delaimy WK, Flatt SW, Natarajan L et al. Igf1 and risk of additional breast cancer in the WHEL Study. Endocr Relat Cancer 2011;18:235-44.
27. Al Awadhi SA, Al Khaldi RM, Al RT, Kapila K, Mojiminiyi OA. Associations of adipokines & insulin resistance with sex steroids in patients with breast cancer. Indian J Med Res 2012;135:500-05.
28. Touvier M, Fezeu L, Ahluwalia N et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177:3-13.
29. Cust AE, Stocks T, Lukanova A et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009;113:567-76.
30. Alokail MS, Al-Daghri N, Abdulkareem A et al. Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer 2013;13:54.
31. Ollberding NJ, Kim Y, Shvetsov YB et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila) 2013;6:188-95.
32. Duggan C, Irwin Ml, Xiao L et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011;29:32-39.
33. Oh SW, Park CY, Lee ES et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 2011;13:R34.
34. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. metaanalysis of observational studies in epidemiology (MOOSE) Group. JAMA 2000;283:2008-12.
35. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
36. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
37. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to metaanalysis. Am J Epidemiol 1992;135:1301-09.
38. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589-624.
39. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001;20:641-54.
40. Von EE, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-49.
41. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE. Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012;13:395-98.
42. Dalamaga M, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G, Lekka A. Hyperresistinemia is associated with postmenopausal breast cancer. Menopause 2013;20:845-51.
43. Ye J, Jia J, Dong S et al.: Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev 2014;23:158-65.
44. Liu Ly, Wang M, Ma ZB et al. The role of adiponectin in breast cancer: a meta-analysis. PLoS One 2013;8:E73183.
45. Goodwin PJ, Ennis M, Pritchard KI et al. Insulin- and obesityrelated variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 2012;30:164-71.
46. Key TJ, Appleby PN, Reeves GK et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
47. Gunter MJ, Hoover DR, Yu H et al.: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60.
48. Maskarinec G, Woolcott C, Steude JS, Franke AA, Cooney RV. The relation of leptin and adiponectin with breast density among premenopausal women. Eur J Cancer Prev 2010;19:55-60.
49. Chen X, Wang Y. Adiponectin and breast cancer. Med Oncol 2010;28:1288-95.
50. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86:S858-66.
51. Fabian CJ. Adiponectin: a risk biomarker and attractive target for chemoprevention. J Clin Oncol 2012;30:124-26.
52. Jarde T, Perrier S, Vasson MP, Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011;47:33-43.
53. Silva FM, De Almeida JC, Feoli AM.: Effect of diet on adiponectin levels in blood. Nutr Rev 2011;69:599-612.
54. Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011;10:1-12.
55. Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res 2013;19:1926-32.